West Mining Corp. Announces Richard Lonsdale-Hands to the Advisory Board

Udgivet den 08-05-2024  |  kl. 08:59  |  

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- WEST MINING CORP. ("WEST" OR THE "COMPANY") (CSE: WEST) (OTC: WESMF) (FRA: 1HL) is pleased to announce the appointment of Richard Lonsdale-Hands to its advisory board. Mr. Lonsdale-Hands is a seasoned investor with over 50 years of experience in investment banking, resources and property management. He has held many significant roles of director, president, managing director and advisor with multiple small and large capitalization companies throughout his career.

Mr. Lonsdale-Hands has managed funds for Robeco, ADIA, BMA, AMP, The Prudential Assurance Co PLC and many other institutional and private clients. He has held and currently holds a number of directorships in companies related to investments made by ADT, ADC, AASF and RFMJ, and has been a guest speaker on European Business at the Dallas Ambassadors Conference 1996.  Other notable roles he's had include being Director of the Chambord Fund, Director of Orco Property Group, and Director of FIPP SA. He has also acted as adviser to numerous worldwide pension funds, asset managers and insurance companies. He is fluent in English and French and spends most of his time between Luxembourg, London and the south of France.

Nader Vatanchi, West Mining's Chief Executive Officer, said, "We welcome Mr. Lonsdale-Hands and his years of experience to the Company. Mr. Lonsdale-Hands brings invaluable insights and strategic guidance to our team from a European standpoint. We look forward to working with him as we continue to progress the Company."

About West Mining Corp.

West Mining Corp. is a mineral exploration company acquiring and developing advanced and early-stage exploration projects. Its flagship project is its 100% owned, 9000-hectare prospective Kena Project located near Nelson, British Columbia.  The Kena Project comprises three adjoining Properties: Kena, Daylight and Athabasca. A recent NI43-101 resource estimate for Kena gave 561,900 oz Au indicated and 2,773,100 oz Au inferred in the Gold Mountain, Kena Gold, and Daylight Zones.  The Daylight property contains the historic past producing Daylight, Starlight, Victoria, Irene, and Great Eastern gold mines. Along trend to the north is the Athabasca Property, with the historic Athabasca Gold Mine. The Company also holds a 100% interest in its Spanish Mountain and Junker properties.

For additional information, please refer to the Company's public disclosure record available on SEDAR+ at www.sedarplus.com.

West Mining Corp.
Nader Vatanchi
778-881-4631
CEO
nadervatanchi@hotmail.com

The Canadian Securities Exchange accepts no responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company, are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to them, and are subject to certain risks, uncertainties and assumptions, including, without limitation: the potential of the Company's mineral properties; the estimation of capital requirements; the estimation of operating costs; the timing and amount of future business expenditures; and the availability of necessary financing. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and exploration or operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. 


\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

12:09 Gubra og Zealand Pharma trækkes med ned af negativt nyt til Novo Nordisk
12:05 Novo lever ikke op til egne forventninger i vigtigt studie - aktien mister 900 mia kr -NY2
11:56 Novo lever ikke op til egne forventninger i kursfølsomt studie - aktien mister 700 mia kr
11:48 Aktier/middag: Zealand Pharma bankes tocifret ned efter FDA-afvisning og trækker C25 ned
11:28 Obligationer/middag: Små renteudsving før inflationsnyt fra USA
10:49 Jefferies ser kurslussing til Zealand Pharma som købsmulighed
10:19 FLSmidth foreslår Mads Nipper som ny bestyrelsesformand
09:18 Zealand Pharma bankes i bund på børsen efter FDA-afvisning - aktionærer taber 5,3 mia. kr.
09:14 Aktier/åbning: Zealand Pharma falder tungt efter FDA-afvisning i rødt C25
09:11 Zealand Pharma bankes i bund på børsen efter FDA-afvisning
08:52 Obligationer/åbning: Små renteudsving før inflationsnyt fra USA
08:23 DNB sænker sin værdiansættelse af Zealand Pharmas Glepaglutid efter FDA-afvisning
08:13 Vigtigt rateindeks for Mærsk stiger for fjerde uge i træk
08:12 Væksten i dansk økonomi i tredje kvartal nedrevideret
08:09 Råvarer: Oliepriserne falder på styrket dollar og stagnerende kinesisk efterspørgsel
08:04 Vigtigt rateindeks for Mærsk stiger for fjerde uge i træk
07:59 Zealand Pharmas aktiekurs kan blive trykket af nye datakrav spår Nordnet
07:50 Aktier/tendens: Zealand Pharma i fokus efter amerikansk afvisning i ventet rødt marked
07:36 Per Aarsleff får hævet kursmål efter regnskab
07:25 Vægttab med Novos Cagrisema på 25 pct. eller mere kan give kursraket spår Nordnet